Your browser doesn't support javascript.
loading
Monitoring Breast Cancer Care Quality at National and Local Level Using the French National Cancer Cohort.
Houzard, Sophie; Courtois, Emilie; Le Bihan Benjamin, Christine; Erbault, Marie; Arnould, Laurent; Barranger, Emmanuel; Coussy, Florence; Couturaud, Benoît; Cutuli, Bruno; de Cremoux, Patricia; de Reilhac, Pia; de Seze, Chantal; Foucaut, Aude-Marie; Gompel, Anne; Honoré, Stéphane; Lesur, Anne; Mathelin, Carole; Verzaux, Laurent; Bousquet, Philippe-Jean.
Afiliação
  • Houzard S; Survey Data Science and Assessment Division, National Cancer Institute, Boulogne Billancourt, France. Electronic address: shouzard@institutcancer.fr.
  • Courtois E; Survey Data Science and Assessment Division, National Cancer Institute, Boulogne Billancourt, France.
  • Le Bihan Benjamin C; Survey Data Science and Assessment Division, National Cancer Institute, Boulogne Billancourt, France.
  • Erbault M; Quality and Safety Care Improvement Department, French National Authority for Health, Saint-Denis La Plaine CEDEX, France.
  • Arnould L; Department of Pathology, GF Leclerc Cancer Centre, Dijon, France.
  • Barranger E; Department of Surgery, Antoine Lacassagne Cancer Centre, Nice, France.
  • Coussy F; Department of Medical Oncology, Institute Curie, Paris, France.
  • Couturaud B; Department of Surgery, Institute Curie, Paris, France.
  • Cutuli B; Department of Radiation Oncology, Courlancy Cancer Clinic, Reims France.
  • de Cremoux P; Saint Louis University Hospital, Paris France.
  • de Reilhac P; Medical Gynecology, Nantes, France.
  • de Seze C; Oise Cancer Screening Association, Compiègne, France.
  • Foucaut AM; Education and Health Promotion Laboratory UR 3412, Université Sorbonne Paris Nord, Bobigny, France.
  • Gompel A; Gynecological Surgery and Oncology, Reproductive Medicine, Cochin University Hospital, Paris, France.
  • Honoré S; Pharmaceutical Expertise and Biomedical Research, La Timone University Hospital, Marseille Cedex 5, France.
  • Lesur A; Department of Senology, Lorraine Cancer Institute - Alexis Vautrin, Vandœuvre-lès-Nancy Lorraine Cancer Institute - Alexis Vautrin, Vandoeuvre Les Nancy, France.
  • Mathelin C; Department of Senology, Strasbourg University Hospital, Strasbourg, France.
  • Verzaux L; Radiology Practice, Le Havre, France.
  • Bousquet PJ; Survey Data Science and Assessment Division, National Cancer Institute, Boulogne Billancourt, France; Aix Marseille University, INSERM, IRD, Economics and Social Sciences Applied to Health & Analysis of Medical Information (SESSTIM), Marseille, France.
Clin Breast Cancer ; 22(7): e832-e841, 2022 10.
Article em En | MEDLINE | ID: mdl-35750594
ABSTRACT

PURPOSE:

The French National Cancer Institute has developed, in partnership with the French National Authority for Health, breast cancer-specific Care Quality, and Safety Indicators (BC QIs). With regard to the most common form of cancer, our aim is to support local and national quality initiatives, to improve BC pathways and outcomes, reduce heterogeneity of practice and regional inequities. In this study, we measure the BC QIs available in the French National medico-administrative cancer database, the French Cancer Cohort, for 2018. MATERIALS AND

METHODS:

BC QIs are developed according to the RAND method. QIs are based on good clinical practice and care pathway recommendations. QI computation should be automatable without any additional workload for data collection. They will be published annually for all stakeholders, and especially hospitals.

RESULTS:

Finally, ten feasible and pertinent QIs were selected. In France, BC care was found to be close to compliance with most QIs proportion of patients undergoing biopsy prior to first treatment (94.5%), proportion of patients undergoing adjuvant radiotherapy after breast-conserving surgery for BC (94.5%), proportion of women undergoing radiotherapy within 12 weeks after surgery and without chemotherapy (86.2%), proportion of DCIS patients undergoing immediate breast reconstruction (54.3%) and proportion of women with NMIBC undergoing breast reintervention (14.4%). However, some are still far from their recommended rate. In particular, some QIs vary considerably from one region, or one patient, to another.

CONCLUSION:

Each result needs to be analyzed locally to find care quality leverage. This will strengthen transparency actions aimed at the public.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Guideline Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Guideline Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article